Atom Investors’s Ginkgo Bioworks DNA Stock Holding History

Atom Investors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,969	Closed	-$110K	–	877
2026 Q1	$110K	Buy	17,969 +5,334	+42%	+$44.4K	0.01%	622
2025 Q4	$105K	Buy	+12,635	New	+$136K	0.01%	528

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Atom Investors's DNA Position: Q2 2026 in Review

Atom Investors sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 17,969 shares — an estimated $110K sold.

Atom Investors first reported a position in DNA in Q4 2025 and held it in 2 quarters. The position peaked at $110K in Q1 2026. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Atom Investors reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
Atom Investors sold 17,969 Ginkgo Bioworks shares in Q2 2026, an estimated $110K.
Atom Investors first reported a position in Ginkgo Bioworks in Q4 2025 and held it in 2 quarters.
Atom Investors's Ginkgo Bioworks position peaked at $110K in Q1 2026.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.